# Senti Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senti-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.sentibio.com/
- Total disclosed funding: $144M
- Latest round: Series B (Jan 6, 2021)
- Investors on record: 22

## About

Senti Biosciences, Inc. is a biotechnology company based in the US that develops advanced cell therapies utilizing proprietary Gene Circuit technology, targeting incurable diseases, with a focus on oncology treatments.Founded in 2016 and headquartered in San Francisco, California, Senti Biosciences, Inc. specializes in creating innovative cell therapies. The company has undergone strategic pivots to refine its focus on Gene Circuit technology. The co-founders, Philip Lee and Tim Lu, have backgrounds in biotechnology, contributing to the company's vision. In its most recent PIPE funding round, Senti Biosciences raised USD 37.60 mn, led by Celadon Partners, with a total amount raised equating to USD 37.60 mn across its seven deals.Senti Bio focuses on developing advanced cell therapies through its proprietary Gene Circuit technology, designed to create smarter medicines for patients with incurable diseases, particularly in the oncology space. Their flagship product candidate, SENTI-202, is currently in clinical trials in the U.S. for the treatment of acute myeloid leukemia (AML). The Gene Circuits are engineered from unique combinations of DNA sequences that reprogram cells to respond intelligently to their environment. This technology aims to enhance the precision of cancer treatments by specifically targeting cancer cells while sparing healthy cells, thereby increasing therapeutic efficacy and reducing side effects. Senti Bio primarily serves patients with cancer and partners with clinical research institutions and healthcare providers in the United States and potentially in other global markets as the company expands its clinical pipeline.Senti Bio's revenue structure is primarily based on collaborations and partnerships within the biopharmaceutical sector. The company engages with healthcare providers and research institutions to conduct clinical trials, which may involve upfront payments and subsequent milestone payments tied to the achievement of specific regulatory or developmental goals. Additionally, upon commercialization of products, revenue may be generated from selling its therapeutics directly to healthcare facilities or through collaborations with larger pharmaceutical companies for broader distribution. While specific pricing plans for their products are not disclosed, the company's focus on innovative therapies suggests a premium pricing strategy reflective of the advanced technology and potential clinical benefits offered by their Gene Circuit-based therapies.Senti Biosciences, Inc. aims to expand its product pipeline with upcoming therapies targeting additional cancer indications and expects to initiate new clinical trials in the next 18 months. The company plans to broaden its market reach, potentially entering international markets in Europe and Asia by 2024. Recent funding will be utilized to support these initiatives, including the development of new product candidates and enhancing its operational capabilities.

## Funding rounds

- Series B, Jan 6, 2021, $105M — Matrix Partners, Menlo Ventures, New Enterprise Associates, Intel Capital, Alexandria Venture Investments, Amgen Ventures, Lux Capital, KB Investment, Mirae Asset Capital, Smilegate Investment, Pear VC, 8VC, Gaingels, LifeForce Capital, LifeSci Partners, Nest.Bio Ventures, Ridgeback Asset Management, Leaps by Bayer, Noveus Capital
- Series A, Feb 27, 2018, $39M — Menlo Ventures, New Enterprise Associates, Allen & Company, Amgen Ventures, Lux Capital, Omega Funds, Pear VC, Goodman Capital, 8VC, LifeForce Capital, Nest.Bio Ventures

## Investors

- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Allen & Company — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Series A, Series B
- Goodman Capital (https://capitalatlas.ai/funds/goodman-capital) — Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A, Series B
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A, Series B
- Nest.Bio Ventures (https://capitalatlas.ai/funds/nest-bio-ventures) — Series A, Series B
- Matrix Partners (https://capitalatlas.ai/funds/matrix-partners) — Series B
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series B
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B
- Ridgeback Asset Management — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B
- Noveus Capital (https://capitalatlas.ai/funds/noveus-capital) — Series B